- Home
- DXCM
DXCM
DexCom Inc.
as 07-11-2025 2:20pm EST
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 34.1B | IPO Year: | 2005 |
| Target Price: | $98.50 | AVG Volume (30 days): | 3.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.33 | EPS Growth: | -13.32 |
| 52 Week Low/High: | $57.52 - $117.19 | Next Earning Date: | 07-30-2025 |
| Revenue: | $4,148,000,000 | Revenue Growth: | 9.11% |
| Revenue Growth (this year): | 16.74% | Revenue Growth (next year): | 15.29% |
Stock Insider Trading Activity of DexCom Inc. (DXCM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Brown Michael Jon | DXCM | EVP, Chief Legal Officer | Jun 16 '25 | Sell | $82.80 | 500 | $41,400.00 | 95,102 | |
| FOLETTA MARK G | DXCM | Director | Jun 16 '25 | Sell | $83.13 | 2,750 | $228,604.75 | 56,621 | |
| AUGUSTINOS NICHOLAS | DXCM | Director | Jun 13 '25 | Sell | $82.25 | 6,290 | $517,906.02 | 37,083 | |
| Stern Sadie | DXCM | EVP, Chief HR Officer | May 27 '25 | Sell | $85.11 | 6,184 | $526,318.38 | 109,621 | |
| Brown Michael Jon | DXCM | EVP, Chief Legal Officer | May 23 '25 | Sell | $84.28 | 10,000 | $842,849.00 | 95,102 |
Latest DexCom Inc. News
DXCM Breaking Stock News: Dive into DXCM Ticker-Specific Updates for Smart Investing
Insider Monkey
13 days ago
Oppenheimer Reaffirms DexCom Buy Rating Amid HHS Wearables Push
Zacks
15 days ago
Here's Why DexCom (DXCM) is a Strong Momentum Stock
StockStory
16 days ago
DexCom’s Q1 Earnings Call: Our Top 5 Analyst Questions
TipRanks
17 days ago
Diabetes stocks rally after RFK comments on HHS campaign
Zacks
17 days ago
Why DexCom (DXCM) is a Top Growth Stock for the Long-Term
Simply Wall St.
17 days ago
Undervalued Stock Opportunities For Savvy Investors In June 2025
Barchart
17 days ago
S&P Futures Tick Higher With Focus on Powell’s Testimony
Argus Research
18 days ago
DXCM: Raising target price to $59.00
Compare DXCM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DXCM DexCom Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.